At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 504 enrolled
Drug / intervention
Dapagliflozin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the Effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients With Preserved Ejection Fraction
In Brief
A Phase 3 clinical trial evaluating Dapagliflozin and Placebo for Heart Failure With Preserved Ejection Fraction (HFpEF). Completed, enrolled 504 participants across 101 sites in 12 countries.
Detailed Summary
International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients with Preserved Ejection Fraction (HFpEF)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesArgentina, Brazil, Bulgaria, Canada, Denmark, Italy, Japan, Slovakia, South Africa, South Korea, Sweden, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedMar 2019
Enrollment StartApr 2019
Primary CompletionJul 2020
TodayJul 2026
First PostedMar 15, 2019
Enrollment StartApr 4, 2019
Primary CompletionJul 9, 2020
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 7.3 years ago
Interventions
Dapagliflozindrug
Tablets administered orally once daily. Treatment start within 24h after randomisation for 16 weeks.
Placeboother
Tablets administered orally once daily. Treatment start within 24h after randomisation for 16 weeks.